iSpecimen 3Q 2026: Revenue $244.03K, EPS ($1.03) — 10-Q Summary
iSpecimen reported 3Q 2026 revenue of $244.03K, up 129% YoY, with specimen count rising 169% to 752. Net loss narrowed 20% due to lower operating expenses. Sales and marketing costs increased 21%, while technology and administrative expenses fell. Quote-to-purchase conversion ratio improved to 44%.
How this was made

The 30-second read
Why it matters
Traders can use the disclosed operating KPIs (specimen volume, ASP, conversion ratio, expense lines) to reassess near-term burn and the sustainability of growth versus pricing pressure.
Market read
A fresh quarterly disclosure with multiple directional operating metrics, but no explicit guidance, keeps the setup more about execution than a definitive re-rating.
What to watch
Quote-to-purchase-order conversion improved to 44%, but the article does not quantify absolute order economics or whether sales and marketing growth (up 21%) is efficiently translating into profitable growth.
Background
The piece is a 10-Q summary for iSpecimen’s 3Q 2026 results, highlighting revenue, loss, operating expense trends, and conversion metrics.
Ticker impact
iSpecimen reports 3Q 2026 revenue of $244.03K and EPS of ($1.03), alongside a 129% revenue rise and a 20% narrower net loss.
Likely modest upside bias as investors focus on revenue growth and expense reductions, tempered by continued losses and falling average selling price.
The article provides multiple directional operating metrics (revenue up, net loss narrowed, operating expenses down) but does not include guidance or a clear profitability inflection.
Market effects
Limited broader sector signal; this is a single microcap-style quarterly operating update with no stated industry-wide catalyst.
No clear regional spillover beyond sentiment for small-cap healthcare/biotech-adjacent names.
No direct global macro or cross-border supply-demand linkage described.
Counterpoint
Revenue growth may be driven by higher specimen volume while pricing weakens (average selling price down 15%), which could cap margin expansion.
Key entities
- companyiSpecimen Inc.
Subject of the 3Q 2026 10-Q summary, reporting revenue growth, narrower net loss, and improved quote-to-PO conversion.


